Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Panacea Biotec Ltd (PANACEABIO)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531349 NSE: PANACEABIO Pharmaceuticals & Drugs | Small Cap | Panacea Biotec Share Price
₹346.35 0.30 (0.09%)
As on 12-Oct'26 16:59
Panacea Biotec Ltd (PANACEABIO)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531349 NSE: PANACEABIO Pharmaceuticals & Drugs | Small Cap | Panacea Biotec Share Price
₹346.35 0.30 (0.09%)
As on 12-Oct'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹2,121 Cr.
Current Price
₹346.4
52-Week Low / High
₹293 / 648
TTM EPS
₹-1.2
TTM Sales
₹673 Cr.
Book Value per Share
₹136.7
P/E Ratio
0.00
Industry PE
52.6
Price to Book (P/B)
2.53
Lower than its 5-year historical median
Price to Sales (P/S)
3.15
Lower than its 5-year historical median
EV/EBITDA
117.82
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-0.86%
Underperforms industry median
Return on Capital Employed (ROCE)
-0.15%
Underperforms industry median
Return on Assets (ROA)
-0.56%
Operating Profit Margin
-0.7%
Net Profit Margin
-1.12%
Gross Profit Margin
1%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
33.44%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
72.48%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹831 Cr.
Equity
₹6.1 Cr.
Face Value
₹1
All Time Low / High
₹3.35 / 647.50
Check Before You Invest
Quality
Not GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Weak
Is Panacea Biotec Ltd a good quality company?
Panacea Biotec Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Panacea Biotec Ltd performance compare with that of its Peers?
Revenue growth of Panacea Biotec Ltd vs industry peers?
Panacea Biotec Ltd revenue CAGR is 0.47%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Panacea Biotec Ltd?
Promoters hold 72.48% of the Panacea Biotec Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Panacea Biotec Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 12.1% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Panacea Biotec Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 1.5% | 3% | 11.5% | 1.1% | -0.7% | -16.1% | -11.4% | 4.1% | -2.1% | -3.4% | - |
| Value Creation Index ⓘ | -0.9 | -0.8 | -0.2 | -0.9 | -1.1 | -2.2 | -1.8 | -0.7 | -1.2 | -1.2 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 530 | 574 | 444 | 490 | 344 | 236 | 257 | 360 | 310 | 413 | 436 |
| Sales YoY Gr. | - | 8.3% | -22.7% | 10.3% | -29.8% | -31.5% | 9.2% | 39.9% | -13.8% | 33.4% | - |
| Adj EPS ⓘ | -6.6 | -11.1 | -32.1 | -19.8 | -2.7 | -15.2 | -14.9 | 0.3 | -2.6 | -4.3 | -3.6 |
| YoY Gr. | - | NA | NA | NA | NA | NA | NA | NA | -870.6% | NA | - |
| BVPS (₹) ⓘ | 74.4 | 63.4 | 68.3 | 140.5 | 83 | 67.8 | 53.2 | 53.7 | 51.3 | 46.6 | 46.8 |
| Adj Net Profit ⓘ | -40.6 | -67.7 | -196 | -121 | -16.6 | -93.2 | -91 | 2.1 | -16 | -26 | -22 |
| Cash Flow from Ops. ⓘ | 104 | 172 | 107 | -82.9 | 38.3 | -52.7 | -10.7 | 33.1 | 3.9 | -40.2 | - |
| Debt/CF from Ops. ⓘ | 9.9 | 5.6 | 6.4 | -0.8 | 1.7 | -1.6 | -9.5 | 3.8 | 58 | -6.6 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -2.7% | 3.8% | 17.2% | 33.4% | ||||
| Adj EPS ⓘ | NA | NA | NA | NA | ||||
| BVPSⓘ | -5.1% | -10.9% | -4.3% | -9.2% | ||||
| Share Price | 12.3% | 5.2% | 27% | -21.3% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -8.2 | -16 | -48.7 | -18.5 | -2.4 | -20.2 | -24.6 | 0.6 | -5 | -8.7 | -7.6 |
| Op. Profit Mgn % ⓘ | 14.7 | 15.2 | -29.5 | 8.2 | 0.2 | -30.6 | -24.2 | 3.9 | -2.2 | -3 | -1.7 |
| Net Profit Mgn % ⓘ | -7.7 | -11.8 | -44.2 | -24.8 | -4.8 | -39.6 | -35.4 | 0.6 | -5.2 | -6.3 | -5 |
| Debt to Equity ⓘ | 2.2 | 2.5 | 1.7 | 0.1 | 0.1 | 0.2 | 0.3 | 0.4 | 0.7 | 0.9 | - |
| Working Cap Days ⓘ | 391 | 359 | 666 | 651 | 576 | 582 | 549 | 393 | 397 | 252 | 132 |
| Cash Conv. Cycle ⓘ | 47 | -8 | 1 | -39 | -20 | 72 | 35 | -18 | 13 | 13 | -14 |
Valuation of Panacea Biotec - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 544 | 593 | 457 | 544 | 625 | 661 | 460 | 559 | 559 | 640 |
| Operating Expenses ⓘ + | 497 | 508 | 590 | 519 | 548 | 674 | 558 | 579 | 585 | 644 |
| Operating Profit ⓘ | 47 | 85 | -133 | 25 | 77 | -13 | -98 | -20 | -26 | -5 |
| Operating Profit Margin (%) | 8.7% | 14.3% | -29.2% | 4.7% | 12.3% | -2.0% | -21.3% | -3.6% | -4.6% | -0.7% |
| Other Income ⓘ + | 47 | 8 | 5 | 30 | 10 | 11 | 52 | 26 | 21 | 17 |
| Interest ⓘ | 101 | 101 | 105 | 174 | 185 | 181 | 4 | 4 | 4 | 6 |
| Depreciation ⓘ | 68 | 59 | 55 | 44 | 46 | 44 | 39 | 37 | 35 | 33 |
| Profit Before Tax ⓘ | -67 | -66 | 46 | -178 | -144 | 1,449 | 13 | 1 | -8 | -7 |
| Tax ⓘ | -11 | 10 | 9 | 17 | 2 | 371 | 47 | 3 | 1 | -0 |
| Profit After Tax | -56 | -76 | 38 | -195 | -146 | 1,078 | -34 | -2 | -9 | -7 |
| PAT Margin (%) | -10.4% | -12.9% | 8.2% | -35.8% | -23.4% | 163.1% | -7.3% | -0.3% | -1.6% | -1.1% |
| Adjusted EPS (₹) | -8.9 | -12.1 | 6.2 | -31.7 | -24.1 | 176.1 | -5.4 | -0.2 | -1.4 | -0.9 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 356 | 309 | 350 | 167 | -229 | 877 | 844 | 842 | 835 | 835 | |
| Debt + | 905 | 736 | 116 | 617 | 735 | 34 | 20 | 21 | 22 | 24 | |
| Minority Interest | 11 | -3 | -3 | -3 | -3 | -3 | -3 | -4 | -4 | -6 | |
| Trade Payables | 249 | 277 | 270 | 199 | 247 | 235 | 177 | 146 | 226 | 190 | |
| Others Liabilities ⓘ | 255 | 274 | 623 | 579 | 427 | 593 | 405 | 408 | 223 | 220 | |
| Total Liabilities ⓘ | 1,774 | 1,592 | 1,356 | 1,559 | 1,177 | 1,735 | 1,443 | 1,412 | 1,301 | 1,262 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 1,001 | 949 | 806 | 657 | 609 | 622 | 600 | 569 | 551 | 560 | |
| CWIP ⓘ | 30 | 40 | 23 | 24 | 34 | 17 | 42 | 101 | 128 | 144 | |
| Investments ⓘ | 7 | 7 | 5 | 6 | 0 | 5 | 13 | 40 | 3 | 10 | |
| Inventories | 316 | 334 | 81 | 148 | 174 | 213 | 202 | 178 | 214 | 193 | |
| Trade Receivables | 142 | 136 | 89 | 69 | 85 | 82 | 60 | 57 | 73 | 74 | |
| Cash Equivalents | 14 | 23 | 23 | 90 | 136 | 583 | 226 | 122 | 107 | 64 | |
| Others Assets ⓘ | 263 | 103 | 329 | 566 | 140 | 213 | 299 | 344 | 226 | 217 | |
| Total Assets ⓘ | 1,774 | 1,592 | 1,356 | 1,559 | 1,177 | 1,735 | 1,443 | 1,412 | 1,301 | 1,262 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 131 | 118 | 105 | -30 | 107 | -108 | -422 | 3 | -27 | 17 |
| Cash Flow From Investing Activity ⓘ + | -26 | 55 | -5 | -35 | -48 | 1,283 | 430 | 7 | 65 | -40 |
| Cash Flow From Financing Activity ⓘ + | -107 | -164 | -101 | 91 | -47 | -1,176 | -18 | -3 | -3 | -1 |
| Net Cash Flow ⓘ | -2 | 9 | -2 | 26 | 12 | -2 | -10 | 7 | 35 | -25 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -34.38 | -22.94 | 11.39 | -75.26 | N/A | 332.85 | -3.92 | -0.18 | -1.04 | -0.86 |
| ROCE (%) | 2.76 | 2.63 | 13.44 | -0.38 | N/A | 217.12 | 1.94 | 0.59 | -0.47 | -0.15 |
| Asset Turnover Ratio | 0.29 | 0.35 | 0.31 | 0.37 | 0.48 | 0.48 | 0.3 | 0.4 | 0.41 | 0.51 |
| PAT to CFO Conversion(x) | N/A | N/A | 2.76 | N/A | N/A | -0.1 | N/A | N/A | N/A | N/A |
| Working Capital Days | ||||||||||
| Receivable Days | 92.80 | 85.20 | 89.80 | 52.80 | 42.70 | 43.70 | 54.60 | 37.70 | 42.20 | 40.90 |
| Inventory Days | 203.10 | 198.90 | 166.10 | 76.90 | 89.70 | 101.60 | 159.80 | 121.90 | 127.20 | 113.90 |
| Payable Days | 532.80 | 512.50 | 579.50 | 545.40 | 397.30 | 335.10 | 297.60 | 256.10 | 339.60 | 270.30 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Panacea Biotec Ltd FAQs
The current trading price of Panacea Biotec on 12-Oct-2026 16:59 is ₹346.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 11-Oct-2026 the market cap of Panacea Biotec stood at ₹2,121.4 Cr
The latest P/E ratio of Panacea Biotec as of 11-Oct-2026 is 0.00.
The latest P/B ratio of Panacea Biotec as of 11-Oct-2026 is 7.40.
The 52-week high of Panacea Biotec is ₹647.5 and the 52-week low is ₹293.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Panacea Biotec is ₹436 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Panacea Biotec Ltd is a below average quality company.
The key valuation ratios of Panacea Biotec Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Panacea Biotec Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Panacea Biotec Ltd
The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.
Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2006), as well as among the top 50 pharmaceutical companies (as per ORG IMS July 2006) of India.
The company has been granted patents across countries like USA, U.K., France, Germany, Italy, Sweden, Denmark, Spain, Finland, Switzerland, The Netherlands, New Zealand, Mexico, Brazil, Nigeria, Zimbabwe, Australia, South Africa, Japan, Russia, Canada, Ukraine, Korea and China are among others.
Collaboration/ Strategic alliances The company has collaborated with Cambridge Biostability, U.K to develop thermo stable vaccines.
It has collaborated with National Institute of Immunology, India for Japanese Encephalitis candidate vaccine.
PBL has entered in strategic alliance with Biotech Consortium India to develop, manufacture and market of Anthrax vaccine.
The company has entered into an in-licensing arrangement with National Institute of Health, USA for use of a peptide based product for generation of hair follicles and hair growth.
The company has collaborated with Netherlands Vaccine Institute for inactivated polio vaccine.
It has collaborated with NRDC- India for Foot & Mouth Disease vaccine for veterinary use and Bio Farma-Indonesia for Measles vaccine.
The exclusive products based on patented Drug Delivery System include Panimun Bioral (Cyclosporine), Willgo, ThankGod (for comprehensive management of haemorrohoids), Xeed (anti-tubercular FDC with innovative Drug Delivery for optimum bioavailability of Rifampicin), Nimulid Safeinject, Nimulid MD, Nimulid Transgel.
Commencing fiscal 2008, the company plans for international marketing of novel NDDS based pharmaceutical formulation products to the international markets, like USA, U.K., Germany, France, Latin American countries and Italy through marketing collaborations and are on the look out for partners for distribution & marketing.
Business areas Research and Development (R&D) – Under this the company primarily focuses on New Chemical Entities (NCE), New Biological Entities (NBE) and Novel Drug Delivery System (NDDS). The company has a team of 200 scientists working on different aspect of research across its four R&D centers.
Vaccines- Under this the company has product portfolio of oral polio vaccines and Hepatitis-B vaccines. It is obtaining pre-qualifications for others vaccines. The company markets its vaccines through Chiron Panacea Vaccines, this is a 50:50 joint venture with Novartis Vaccines, U.K
Formulations- It has created flagship brands like Willgo for pain management, Glizid & Glizid-M for diabetes; Panimun Bioral and Mycept for kidney transplant.
Panacea Biotec in 2009 signed an agreement with Popular Pharma for technology transfer, marketing and distribution of vaccines. Popular Pharma is engaged in manufacturing life saving drugs and has presence in various countries.
In 2010 Panacea Biotech's Baddi unit gets US FDA approval
In 2011 PanaceBiotec - Panacea Biotec Launches - PacliALL
In 2012 Panacea Biotech launches Inactivated Polio Virus vaccine in Nigeria
PanaceBiotec - Panacea Biotec inaugurates state of the art Oncology Production Unit
PanaceBiotec - Panacea Biotec Entered into Strategic Alliance with Osmotica Pharmaceutical
Panacea Biotec wins order worth Rs 187 cr from Govt to supply polio vaccines.
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
